Jiangsu Hengrui Pharmaceuticals (SHA: 600276) and Kailera Therapeutics have unveiled Phase II trial data for their obesity drug HRS9531, a GLP-1/GIP receptor dual agonist.
The findings, which show 21.1% placebo-adjusted weight loss at 36 weeks, suggest the treatment could challenge established market leaders in the competitive obesity space.
The Chinese study involved 61 participants with overweight or obesity, with 49 receiving a once-weekly 8 mg dose of HRS9531. Nearly 60% of those treated achieved a weight loss of at least 20%, and weight reduction continued beyond the 36-week mark.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze